Last reviewed · How we verify
Fetal porcine cells, Neurocell-PD
Fetal porcine cells, Neurocell-PD is a Small molecule drug developed by Genzyme, a Sanofi Company. It is currently in Phase 2 development.
At a glance
| Generic name | Fetal porcine cells, Neurocell-PD |
|---|---|
| Sponsor | Genzyme, a Sanofi Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fetal porcine cells, Neurocell-PD CI brief — competitive landscape report
- Fetal porcine cells, Neurocell-PD updates RSS · CI watch RSS
- Genzyme, a Sanofi Company portfolio CI
Frequently asked questions about Fetal porcine cells, Neurocell-PD
What is Fetal porcine cells, Neurocell-PD?
Fetal porcine cells, Neurocell-PD is a Small molecule drug developed by Genzyme, a Sanofi Company.
Who makes Fetal porcine cells, Neurocell-PD?
Fetal porcine cells, Neurocell-PD is developed by Genzyme, a Sanofi Company (see full Genzyme, a Sanofi Company pipeline at /company/genzyme-a-sanofi-company).
What development phase is Fetal porcine cells, Neurocell-PD in?
Fetal porcine cells, Neurocell-PD is in Phase 2.